Moderna Raises Full-Year Revenue Growth Outlook Following Surprise Third-Quarter Profit

10:33 AM EST, 11/06/2026 (MT Newswires) -- Moderna (MRNA) raised its full-year revenue growth outlook on Friday and swung to a surprise third-quarter profit year over year amid strong international sales of the drugmaker's COVID-19 vaccine. The company now expects revenue to grow by 15% to 25% in 2026, compared with its previous forecast for growth of up to 10%. The consensus on FactSet is for sales to grow by 8.1% for the current year. Moderna's shares were up 3.4% in Friday trade. The stock has surged 718% so far this year. For the September quarter, the company swung to earnings of $0.38 a share from a loss of $0.51 the year before, defying the Street's view for a loss of $1.13. Revenue climbed to $1.31 billion from $1.02 billion, beating the average analyst estimate for a decline to $890.3 million, mainly driven by higher COVID-19 vaccine sales in international markets, supported by deliveries under long-term strategic government partnerships. Net product sales increased to $1.27 billion from $973 million a year earlier. "We delivered 29% revenue growth in the third quarter, alongside the US approval of mFLUSIVA, our fifth approved product globally, and positive phase 3 results for intismeran in melanoma," Chief Executive Stephane Bancel said in a statement. Last month, Moderna and Merck (MRK) announced that their experimental skin cancer treatment, intismeran, combined with Merck's Keytruda, reduced the risk of recurrence or death by 42% in patients with resected high-risk melanoma, compared with Keytruda alone. Moderna received approval from the US Food and Drug Administration for its seasonal influenza vaccine mFLUSIVA in August. The company is conducting a limited US launch of the product for the 2026-2027 influenza season, with approval occurring after the annual contracting cycle. "Looking ahead, we anticipate additional intismeran readouts, pivotal data in propionic acidemia and further regulatory approvals as we advance our pipeline and build a more diversified company," Bancel said. Earlier in the week, Pfizer (PFE) raised its full-year outlook and reported better-than-expected third-quarter results, despite double-digit declines in sales of its COVID-19 products. Last month, pharmaceutical giant Johnson & Johnson (JNJ) lifted its guidance for 2026 amid better-than-expected quarterly results. Price: 260.67, Change: +19.21, Percent Change: +7.96